MCT Food Composition for Epilepsy Seizure Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epilepsy in humans and animals, including dogs, often involve antiepileptic drugs (AEDs) that are not effective for all patients, and traditional ketogenic diets can be restrictive and unpalatable, leading to suboptimal seizure control and quality of life issues.
Innovation Solution
A food composition containing medium chain triglycerides (MCTs) with a balanced diet of high protein and carbohydrate, providing 1-15% of calories from MCTs, is used in conjunction with AEDs to enhance therapeutic efficacy, reducing seizure frequency by at least 50% compared to diets without MCTs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional ketogenic diets with 4:1 fat to protein plus carbohydrates ratio are used to treat epilepsy, then seizure control is improved, but dietary restrictiveness and unpalatability increase
Solution Approach 1:
The patent changes the macronutrient ratio parameter from the traditional 4:1 fat to protein plus carbohydrates ratio to a new ratio of 1.2:1, while specifically incorporating 10-20% medium chain triglycerides (MCTs) into the diet. This parameter modification maintains the ketogenic effect for seizure control while significantly improving dietary acceptability and reducing restrictiveness
Solution Approach 2:
The patent creates a composite dietary formulation that combines multiple fat sources including MCTs (10-20%), long chain triglycerides (70-80%), and other fatty acids. This composite approach allows the diet to maintain therapeutic efficacy while improving palatability and reducing dietary restrictiveness through a more balanced and varied composition
2Reliability
If antiepileptic drugs are administered to achieve seizure control, then seizure frequency is reduced, but side effects such as ataxia, polyphagia, polyuria, polydipsia and incontinence increase
Solution Approach 1:
The patent introduces a specially formulated diet containing MCTs as an intermediary therapeutic approach. This dietary intervention works synergistically with AEDs to enhance seizure control while potentially allowing for reduced AED dosing, thereby minimizing drug-related side effects such as ataxia, polyphagia, polyuria, polydipsia and incontinence
Solution Approach 2:
The patent converts the potential harm of requiring high doses of AEDs (which cause side effects) into a benefit by using the MCT-containing diet as an adjunctive therapy. This allows for lower AED dosing while maintaining or improving seizure control, thus transforming the situation from one dominated by drug side effects to one where the diet provides therapeutic benefit with fewer adverse effects
3Reliability
If classic ketogenic diets with high fat content are used to treat epilepsy, then seizure reduction is achieved, but palatability decreases
Solution Approach 1:
The patent modifies the dietary parameters by incorporating 10-20% MCTs and adjusting the overall fat to protein plus carbohydrates ratio to 1.2:1, which improves palatability while maintaining or enhancing seizure reduction efficacy compared to traditional high-fat ketogenic diets
Solution Approach 2:
The patent formulates a composite dietary fat mixture combining MCTs (10-20%), long chain triglycerides (70-80%), and other fatty acids in specific proportions. This composite formulation improves palatability and dietary acceptability while maintaining the ketogenic effect necessary for seizure reduction
Data Source
AI summary
The invention provides compositions and methods for treatment of epilepsy in an animal. In one embodiment, a dietary regime suitable for enhancing the effect of an anti-epileptic drug (AED) in an animal can comprise a food composition comprising a medium chain triglyceride (MCT) and the AED, wherein the MCT is present in the food composition in an effective amount for enhancing the effect of the AED when the food composition and the AED are administered to the animal.